Key result
In patients receiving ICDs or CRT-Ds for primary prevention, programming for antitachycardia pacing successfully terminated 92% of ventricular tachycardia episodes.
Why the study?
Does antitachycardia pacing (ATP) improve successful termination of ventricular tachycardia in patients with ICDs or CRT-Ds for primary prevention?
Observational (n=830)
Yes
Does antitachycardia pacing (ATP) improve successful termination of ventricular tachycardia in patients with ICDs or CRT-Ds for primary prevention?
Programming antitachycardia pacing in primary prevention ICD/CRT-D patients successfully terminates the vast majority of ventricular tachycardia episodes, potentially reducing the need for painful shocks.
Answers are grounded in this paper and cite their sources.
ATP programming in primary prevention ICDs was associated with high VT termination rates; leaves open whether it reduces shocks or improves outcomes.
OBJECTIVES: the PROVE trial was designed to determine if antitachycardia pacing (ATP) is clinically beneficial for primary prevention in patients who have implantable cardioverter defibrillators (ICDs) or cardiac resynchronization therapy defibrillators (CRT-Ds). BACKGROUND: use of ICDs and CRT-Ds reduces mortality in patients with ventricular dysfunction and mild to moderate heart failure. However, in studies of the primary prevention population, shock-only ICDs are predominantly used, without ATP programming for less painful termination of ventricular tachycardia (VT). METHODS: we conducted a prospective, nonrandomized, multicenter study using market-released ICDs and CRT-Ds. Patients received devices programmed to deliver ATP for VT cycle lengths of 270-330 ms. Follow-up evaluation was performed at 3, 6, and 12 months. The incidence of VT and the rate of successful termination by ATP were analyzed. RESULTS: of 830 patients in the study population (men, 73%; mean age, 67.3 ± 12 years), 32% received single-chamber ICDs, 44% dual-chamber ICDs, and 24% CRT-Ds. ATP was attempted for 112 VT episodes in 71 patients, and 103 (92%) of the VT episodes were successfully terminated. Three VT episodes were accelerated by ATP and required termination by ICD shock; 6 episodes terminated spontaneously or by ICD shock. CONCLUSIONS: VT is common in patients without a history of this arrhythmia who have received ICDs or CRT-Ds for primary prevention indications. Programming ICDs for ATP therapy at the time of implantation could potentially terminate most VT episodes and reduce the number of painful shocks for these patients.
No takes yet. Share an insight, caveat, or question.
Saeed et al. (2010) conducted an observational in Primary prevention of sudden cardiac death (n=830). Antitachycardia pacing (ATP) programming was evaluated on Successful termination of ventricular tachycardia (VT) by ATP. In patients receiving ICDs or CRT-Ds for primary prevention, programming for antitachycardia pacing successfully terminated 92% of ventricular tachycardia episodes.
Synapse has enriched 10 related papers. Consider them for comparative context: